カテゴリ： GlobalData, スウェーデン, 企業調査

Diamyd Medical AB (DMYD B)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Diamyd Medical AB (DMYD B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7942
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：58
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スウェーデン
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Diamyd Medical AB (Diamyd), formerly Diamyd Therapeutics AB is a drug development company that offers diabetes vaccine. The company’s diabetes products include Diamyd, an antigen-based immunotherapy for the treatment of autoimmune diabetes. Its pipeline products include GAD, GABA, and other immunomodulatory agents. Diamyd’s GABA or gamma-aminobutyric acid is synthesized from the amino acid glutamate in cells by the enzyme GAD which helps in the regulation of metabolism and the immune system. The company develops treatment for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technology. Diamyd is headquartered in Stockholm, Sweden.

Diamyd Medical AB (DMYD B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Diamyd Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Diamyd Medical AB, Medical Devices Deals, 2012 to YTD 2018 10
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Diamyd Medical Enters into Partnership with Cardiff University 12
Diamyd Medical Enters into Agreement with TFS Trial Form Support 13
Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 14
Licensing Agreements 15
Diamyd Medical Enters into Licensing Agreement with University of California 15
Diamyd Medical Enters into Licensing Agreement for Gliadin 16
Equity Offering 17
Diamyd Medical Raise USD10 Million in Rights Offering of Units 17
Diamyd Medical Raises USD2.6 Million in Rights Offering of shares 18
Diamyd Medical to Raise USD1.7 Million in Private Placement of Series B Shares 19
Acquisition 20
Diamyd Medical Acquires 16% Stake in NextCell Pharma 20
Diamyd Medical AB – Key Competitors 21
Diamyd Medical AB – Key Employees 22
Diamyd Medical AB – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Oct 11, 2017: Diamyd Medical : Financial Statement 16/17 24
Apr 05, 2017: Diamyd Medical: Quarterly Report II 16/17 25
Jan 25, 2017: Diamyd Medical: Quarterly Report I 16/17 29
Corporate Communications 30
Jan 10, 2017: GABA-specialist to the Board of Diamyd Medical 30
Product News 31
07/27/2017: Additional Preliminary Interim Results From Intralymphatic Study with Diamyd Published as part of Scientific Correspondence in NEJM 31
07/06/2017: Interim Report From Diagnode-1 Supports Continued Positive Clinical Course After 15 Months 32
06/12/2017: Autoantigen GAD-Vaccine is Safe for Children at High Risk for Developing Type 1 Diabetes 33
06/09/2017: New interim report for Diamyd directly into the lymph node indicates continued positive clinical course 34
05/18/2018: Update regarding the manufacturing of Diamyd drug substance 35
05/07/2018: Results supporting intralymphatic administration of Diamyd published in the Journal of Diabetes Research 36
03/27/2017: 30 month results from DIABGAD-1 support effect after partial remission phase 37
03/12/2018: Interim report from DIAGNODE-1 shows continued positive clinical course 38
01/08/2018: The diabetes vaccine Diamyd shows continued positive clinical course after 30 months 39
01/05/2017: Last participant has completed last visit in a five-year prevention trial with Diamyd 40
Clinical Trials 42
Jul 04, 2018: The GABA/Diamyd trial in the US now fully recruited 42
Apr 23, 2018: 50% enrollment milestone reached in Diamyd Medical’s European Phase II trial 43
Mar 02, 2018: Operational update on the diabetes vaccine Diamyd and recombinant GAD 44
Feb 22, 2018: The GABA/Diamyd trial in the US fully recruited this summer 45
Feb 09, 2018: High interest from patients to participate in the DIAGNODE-2 trial 46
Dec 11, 2017: The diabetes vaccine Diamyd shows positive results 47
Nov 13, 2017: Diamyd Medical: Phase II-trial DIAGNODE-2 ahead of World Diabetes Day now open to include patients 48
Oct 27, 2017: Diamyd Medical: Update concerning prevention studies with the diabetes vaccine Diamyd 49
Sep 27, 2017: Update on the strategic development of the study drug Remygen 50
Sep 21, 2017: Phase II trial DIAGNODE-2 with the diabetes vaccine Diamyd approved to start in all participating countries 51
May 22, 2017: Diamyd Medical submits application to the Medical Products Agency for the DIAGNODE-2 trial 52
May 19, 2017: Diamyd in combination with etanercept and vitamin D shows safety after six months 53
May 10, 2017: Article by Professor Johnny Ludvigsson on clinical trials with Diamyd published in Expert Opinion on Biological Therapy 54
Apr 21, 2017: Diamyd Medical enters agreement with global CRO for the DIAGNODE-2 trial 55
Mar 31, 2017: Swine influenza vaccination might have had an impact on treatment with the diabetes vaccine Diamyd in Phase III clinical trial 56
Feb 16, 2017: Previously announced preliminary interim results from intralymphatic study with Diamyd published in the New England Journal of Medicine 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Diamyd Medical AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Diamyd Medical AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Diamyd Medical AB, Deals By Therapy Area, 2012 to YTD 2018 9
Diamyd Medical AB, Medical Devices Deals, 2012 to YTD 2018 10
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Diamyd Medical Enters into Partnership with Cardiff University 12
Diamyd Medical Enters into Agreement with TFS Trial Form Support 13
Diamyd Medical Enter into Partnership with Janssen R&D, JDRF and UAB 14
Diamyd Medical Enters into Licensing Agreement with University of California 15
Diamyd Medical Enters into Licensing Agreement for Gliadin 16
Diamyd Medical Raise USD10 Million in Rights Offering of Units 17
Diamyd Medical Raises USD2.6 Million in Rights Offering of shares 18
Diamyd Medical to Raise USD1.7 Million in Private Placement of Series B Shares 19
Diamyd Medical Acquires 16% Stake in NextCell Pharma 20
Diamyd Medical AB, Key Competitors 21
Diamyd Medical AB, Key Employees 22

List of Figures
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Diamyd Medical AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Diamyd Medical AB, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Diamyd Medical AB (DMYD B)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Cinemark Holdings Inc (CNK)：企業の財務・戦略的SWOT分析
    Cinemark Holdings Inc (CNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Kenya Electricity Generating Co Ltd (KGEN)：電力：M&Aディール及び事業提携情報
    Summary Kenya Electricity Generating Co Ltd (KenGen) is an electricity generation utility. It produces power from hydro, geothermal, thermal, and wind sources. Under power purchase agreements, the company sells power to customers on wholesale basis. Kenya Power and Lighting Company Limited is the au …
  • Chemed Corp (CHE)：企業の財務・戦略的SWOT分析
    Summary Chemed Corp (Chemed) is a diversified company. The company operates through its segments including Vitas and Roto-Rooter. Its Vitas segment provides end-of-life hospice care for heart disease, stroke, multiple sclerosis, lung disease, liver disease, and kidney diseases, among others. Chemed …
  • Orliman SLU：医療機器：M&Aディール及び事業提携情報
    Summary Orliman SLU (Orliman), a subsidiary of The Riverside Company, is a medical device company that develops and manufactures orthopedic products. The company provides products such as stabilizers, immobilizers, lumbosacral back supports, abdominal bands, abdominal belt, shoulder supports, truss, …
  • Otello Corp ASA (OTELLO)：企業の財務・戦略的SWOT分析
    Otello Corp ASA (OTELLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Telkom SA SOC Limited：企業の戦略・SWOT・財務情報
    Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report Summary Telkom SA SOC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • NEC Corp (6701)：企業の財務・戦略的SWOT分析
    NEC Corp (6701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Koninklijke Wessanen N.V.：企業の戦略・SWOT・財務情報
    Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report Summary Koninklijke Wessanen N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Transmissora Alianca de Energia Eletrica SA (TAEE11)：企業の財務・戦略的SWOT分析
    Transmissora Alianca de Energia Eletrica SA (TAEE11) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s k …
  • Neurim Pharmaceuticals Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Neurim Pharmaceuticals Ltd (Neurim) is a drug discovery company that develops drugs for central nervous system diseases.The company's product line includes circadin that is used in insomnia treatment. Neurim offers paediatric prolonged-release melatonin, piromelatine, NEU-P12 and NEU-240. Th …
  • Senju Pharmaceutical Co Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Senju Pharmaceutical Co Ltd (Senju) researches, develops, manufactures and markets pharmaceutical products for eye, ear, nose, throat, and skin. The company offers a wide range of ophthalmological products. Its product portfolio includes prescription products, OTC medicines and veterinary dr …
  • Xtant Medical Holdings Inc (XTNT)：医療機器：M&Aディール及び事業提携情報
    Summary Xtant Medical Holdings Inc (Xtant Medical), formerly Bacterin International Holdings Inc, is a medical device company that develops regenerative medicine products and medical devices. The company’s products include 3Demin, osteosponge, osteosponge SC, osteoselect DBM Putty, OsteoSTX, osteowr …
  • Hydro-Quebec：電力：M&Aディール及び事業提携情報
    Summary Hydro-Quebec is a government-owned energy utility that generates, transmits and distributes electricity. The company specializes in renewable energy generation, using hydro sources and supports the development of electricity using other technologies such as wind energy and biomass. It genera …
  • Water Intelligence PLC (WATR)：企業の財務・戦略的SWOT分析
    Summary Water Intelligence plc (Water Intelligence) formerly Qonnectis Plc, is a clean technology company that offers environmental and technology services. The company offers services such as finding, detecting, and remediating water leaks services. It monitors and protects water infrastructure and …
  • Pluristem Therapeutics Inc (PSTI)：企業の財務・戦略的SWOT分析
    Summary Pluristem Therapeutics Inc (Pluristem) is a clinical-stage biotherapy company that focuses on the development of placental-derived cell therapies. Its PLacental eXpanded (PLX) cells are adherent stromal cells that can be administered to patients without tissue or genetic matching. The compan …
  • Baytex Energy Corp (BTE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Baytex Energy Corp (Baytex Energy) is an independent upstream oil and gas company. It conducts the acquisition, development and production of petroleum and natural gas at its properties in the Western Canadian Sedimentary basin and in the Eagle Ford the US. The company’s products include hea …
  • Allergy Therapeutics Plc (AGY)：企業の財務・戦略的SWOT分析
    Allergy Therapeutics Plc (AGY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Bankinter, S.A.：企業のM&A・事業提携・投資動向
    Bankinter, S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bankinter, S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • University of Texas MD Anderson Cancer Center：企業の戦略的SWOT分析
    University of Texas MD Anderson Cancer Center - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …
  • Chori Co Ltd (8014)：企業の財務・戦略的SWOT分析
    Chori Co Ltd (8014) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆